Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for instructions and the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2018 | (b) 2019 | (c) 2020 | (d) 2021 | (e) 2022 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | ||||||
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf.... | ||||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 4 | Total. Add lines 1 through 3 | ||||||
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f) .. | ||||||
| 6 | Public support. Subtract line 5 from line 4. | ||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2018 | (b) 2019 | (c) 2020 | (d) 2021 | (e) 2022 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | ||||||
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | ||||||
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | ||||||
| 11 | Total support. Add lines 7 through 10 | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2018 | (b) 2019 | (c) 2020 | (d) 2021 | (e) 2022 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | 470,567 | 604,016 | 563,708 | 1,085,260 | 1,059,349 | 3,782,900 |
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | 113,753 | 209,237 | 68,888 | 68,700 | 101,259 | 561,837 |
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | 0 | |||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | 0 | |||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | 0 | |||||
| 6 | Total. Add lines 1 through 5 | 584,320 | 813,253 | 632,596 | 1,153,960 | 1,160,608 | 4,344,737 |
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | 30,470 | 75,000 | 100,176 | 199,532 | 135,163 | 540,341 |
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | 0 | |||||
| c | Add lines 7a and 7b.. | 30,470 | 75,000 | 100,176 | 199,532 | 135,163 | 540,341 |
| 8 | Public support. (Subtract line 7c from line 6.) | 3,804,396 | |||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2018 | (b) 2019 | (c) 2020 | (d) 2021 | (e) 2022 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | 584,320 | 813,253 | 632,596 | 1,153,960 | 1,160,608 | 4,344,737 |
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | 3,067 | 2,245 | 72 | 28 | 5,095 | 10,507 |
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | 0 | |||||
| c | Add lines 10a and 10b. | 3,067 | 2,245 | 72 | 28 | 5,095 | 10,507 |
| 11 | Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on. | 0 | |||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | 0 | |||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | 587,387 | 815,498 | 632,668 | 1,153,988 | 1,165,703 | 4,355,244 |
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by 0.035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | 1 | |
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
2 | |
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | 3 | |
| 4 Amounts paid to acquire exempt-use assets | 4 | |
| 5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI) | 5 | |
| 6 Other distributions (describe in Part VI). See instructions | 6 | |
| 7Total annual distributions. Add lines 1 through 6. | 7 | |
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
8 | |
| 9 Distributable amount for 2022 from Section C, line 6 | 9 | |
| 10 Line 8 amount divided by Line 9 amount | 10 | |
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2022 |
(iii) Distributable Amount for 2022 |
|
|---|---|---|---|---|
| 1 Distributable amount for 2022 from Section C, line 6 | ||||
|
2
Underdistributions, if any, for years prior to 2022 (reasonable cause required-- explain in Part VI).
See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2022: | ||||
| a From 2017....... | ||||
| b From 2018....... | ||||
| c From 2019....... | ||||
| d From 2020....... | ||||
| e From 2021....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2022 distributable amount | ||||
|
i
Carryover from 2017 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from line 3f. | ||||
| 4Distributions for 2022 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2022 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from line 4. | ||||
|
5
Remaining underdistributions for years prior to 2022, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2022. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2023. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2018..... | ||||
| b Excess from 2019..... | ||||
| c Excess from 2020..... | ||||
| d Excess from 2021..... | ||||
| e Excess from 2022..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|
| Software ID: | 22015553 |
| Software Version: | 2022v5.0 |
Attach to Form 990 or 990-EZ.
Go to www.irs.gov/Form990 for the latest information.
| Return Reference | Explanation |
|---|---|
| Form 990, Part VI, Section B, Line 11b | A DRAFT OF THIS RETURN IS FIRST REVIEWED BY THE CHAIRPERSON AND THENDISTRIBUTED TO THE BOARD MEMBERS FOR REVIEW, QUESTIONS AND COMMENTS. |
| Form 990, Part VI, Section B, Line 12c | ANNUALLY CARE DISTRIBUTES THE CONFLICT OF INTEREST POLICY TO EVERY BOARDMEMBER. ALL BOARD MEMBERS ARE REQUIRED TO ATTEST THAT THEY ARE INCOMPLIANCE WITH THE POLICY AND ARE REQUIRED TO SIGN A STATEMENT CONFIRMINGCOMPLIANCE. PRIOR TO THE ELECTION OF ANY NEW BOARD MEMBER, THEY TOOARE REQUIRED TO REVIEW THE POLICY AND SIGN A STATEMENT CONFIRMINGCOMPLIANCE. THE POLICY REQUIRES ANY TRANSACTIONS THAT INVOLVE A BOARDMEMBER, OR A RELATION OF A BOARD MEMBER, BE BROUGHT TO THE ATTENTION OF ANDAPPROVED BY THE BOARD TO APPROVE, PRIOR TO ENTERING INTO ANY TRANSACTION.ANY TRANSACTIONS THAT ARE DEEMED "MATERIAL", NOT CONSISTENT WITH MARKETPRICING, OR GREATER THAN 5% OF REVENUES, WILL NOT BE ENTERED INTO UNDER THEESTABLISHED POLICY. THE CARE SECRETARY MAINTAINS THE FILE OF DOCUMENTSSIGNED BY ANY BOARD MEMBERS CONFIRMING COMPLIANCE. |
| Form 990, Part VI, Section C, Line 19 | No documents available to the public. |
| FORM 990, PART III, LINE 4A - PROGRAM SERVICE ACCOMPLISHMENTS | Mayo Clinic Genomic Early Detection of CancersCARE Fiscal Year Ending June 30, 2023Award Granted $397,304Background and DiscussionMost cancers are diagnosed too late for curative treatments. Modern systemic and targeted drugs for treating advanced cancers are expensive, and some have limited efficacy. Unfortunately, only a few cancers have screening available to detect early, potentially curable, forms. Population-wide screening is available for breast, colorectal, cervical and (in high-risk persons) lung cancers. To improve screening efforts and early diagnosis, Mayo Clinic researchers are working to develop a single blood test that could screen for multiple cancers, including deadly cancers like ovarian or pancreatic cancer.Novel genomic technologies can now detect cancers in the blood, giving rise to a new paradigm of multicancer early detection (MCED). A blood sample is well suited for detection of cancer biomarkers as it contains circulating tumor cells and tumor cell-free DNA (cfDNA) that have been shed from an early developing cancer. An MCED test would analyze these genomic features of the circulating DNA, distinguish it from background signals, and determine where the tumor originated to guide subsequent testing to establish a firm cancer diagnosis, hopefully during a presymptomatic and highly curable early stage. Patients with mutations in BRCA1, BRCA2 and the mismatch repair (MLH1, MSH2, MSH6, PMS2, EPCAM) genes are associated with some of the highest risk of developing cancers, including breast, ovarian, colorectal and uterine, among others. These syndromes hereditary breast and ovarian cancer (HBOC) and Lynch affect approximately 1% of the population but carry a 90%-100% risk of developing cancer.Currently these patients undergo intensive cancer screening or even prophylactic surgery to remove the at- risk organs. A blood-based cancer screening strategy could revolutionize the care of patients with a genetic predisposition to cancer.Mayo Clinic previously conducted the Tapestry study, recruiting more than 60,000 patients who underwent Exome+ sequencing on a saliva sample. To date, Tapestry has identified 700 patients (1.2%) with Lynch and HBOC syndrome. These patients are actively monitored at Mayo Clinic and area institutions for development and prevention of cancer and undergo intensive cancer screening and prophylactic preventive surgeries.ApproachThough a perfect MCED test could theoretically be applied to the general population, this requires further study prior to implementation and replacement of existing proven cancer screening modalities. An alternative earlier step would be to offer MCED to a high-risk cancer population, such as those with genetic predisposition Lynch and HBOC syndrome. An annual blood test that can screen for multiple cancers would provide significant value to patients at risk of cancers in multiple organs and potentially reduce or augment the use of the current intensive surveillance strategies.ProposalWe propose enrolling a subset of Tapestry patients into a longitudinal study using an MCED test.The population includes 700 patients with high-risk cancer predisposition genetic syndromes such as Lynch and HBOC syndrome and a random sample of 4,000 controls who were negative for the Tier 1 CDC genes. Patients would be followed annually as part of the Tapestry study to assess their health care utilization (cancer screening, prophylactic surgery) and incident cancer diagnosis while undergoing standard cancer screening.This would be a pragmatic trial of the use of MCED in a high-risk population and provide the ability to identify the use of this technology in a rapid nature due to the higher cancer risk.SummaryThis study has the potential to revolutionize our approach to cancer screening for patients with the highest risk and expand the use of MCED to the general population.Honor health Research Institute (HHRI) - Rare Cancer InitiativesCARE Fiscal Year Ending June 30, 2023Award Granted $397,304BackgroundThe evolution of the Rare Cancer Initiative has seen the expansion of the elements of the translational science program to include the following initiatives:Plant Extracellular Vesicle ProjectFocus on the development of plant exosomes as delivery vehicles for treatment in TGCT and given the unique driver mutation situation, the treatment of gastrointestinal stromal tumors, another rare sarcoma. This project will require us to obtain tumor specimens to set up organoid/ASTEROID cellular foundations for testing of the plant EV therapeutic options. This includes the use of targeted therapy for TGCT and targeted therapy for GIST. Silicon Nanoparticle TherapyThis project is being derived for use of treatment of relapsed or progressive uveal melanoma but has the potential to be applied to the treatment of the rare pediatric cancer retinoblastoma. We are in the process of further developing the treatment algorithm in the laboratory setting with a view to obtaining grant funding to support the pre-clinical and future clinical testing of this treatment option. Predictive Biomarkers for Uveal MelanomaContinue our research and expand the uveal melanoma EV program to study another 40 samples for protein and RNA EV in order to better characterize the EV expression patterns of uveal melanoma primary tumors, uveal melanoma metastases and cutaneous melanoma metastases. In addition, we are focusing on the expansion of the ctDNA expression patterns to complement the EV expression patterns. The goal is to develop and validate a pattern of expression that can be used to identify patients with occult metastatic disease/high risk disease post resection and to use the expression patterns as a treatment response surrogate for relapse (given the expected timing of relapse) towards the goal of validating effective adjuvant therapy. TGCT Synovial Fluid AnalysisEstablishing the diagnosis of TGCT is difficult and requires surgical procedures that have the potential to cause untoward outcomes in terms of functionality of the involved joint. Major surgical resection is being used exclusively in patients with resectable nodule TGCT but not in patients with diffuse TGCT. The ability to diagnose TGCT with a less invasive process including multi-omic analysis of the fluid and the radiologic findings would be a significant advance in the management of these patients. SummaryWhile the projects identified have a relatively small incidence rate in the general population, they nonetheless have a significant impact to individuals affected. Uveal Melanoma only has a 66% survival rate at 5 years once spread to surrounding tissues and organs. Rare cancer initiatives are designed to initially treat the underlying disease in Arizona; however, our learnings will be disseminated broadly through a variety of mechanisms among healthcare providers including participation in studies. Moreover, our learnings in predictive biomarkers and plant exosomes are translatable to other cancer treatment programs. |
| Software ID: | 22015553 |
| Software Version: | 2022v5.0 |